Anti-CCR8 monoclonal antibody designed to deplete/suppress CCR8+ tumor-infiltrating regulatory T cells and relieve immunosuppression.
Anti-CCR8 monoclonal antibody that targets CCR8 on tumor-infiltrating regulatory T cells, blocking CCL1–CCR8 signaling and depleting/suppressing CCR8+ Tregs in the tumor microenvironment to relieve immunosuppression and restore antitumor immune responses.
YES
DIRECT
Antibody binding to CCR8 flags CCR8+ Tregs for Fc-mediated clearance, inducing ADCC/ADCP (and possibly CDC) by effector cells, leading to depletion of CCR8-expressing cells.
A humanized, defucosylated IgG1 monoclonal antibody targeting CCR4 on malignant cutaneous T cells and regulatory T cells; enhances NK cell–mediated ADCC and depletes CCR4+ cells.
Humanized, defucosylated IgG1 monoclonal antibody that binds CCR4 on malignant T cells and regulatory T cells; blocks CCR4 signaling and enhances NK cell–mediated ADCC via Fc receptor engagement, leading to depletion of CCR4+ cells and antitumor/immunomodulatory effects.
YES
DIRECT
Anti-CCR4 IgG1 binds CCR4 on target cells and engages Fcγ receptors on NK cells to trigger ADCC, depleting CCR4+ cells (with possible contribution from ADCP/CDC).
Izalontamab brengitecan (BMS-986507), a bispecific EGFR/HER3-targeted antibody–drug conjugate that is internalized upon binding and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific EGFR/HER3-targeted antibody–drug conjugate that binds EGFR- and HER3-expressing tumor cells, is internalized, and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
YES
DIRECT
An EGFR/HER3-targeted ADC binds EGFR on tumor cells, is internalized, and releases a topoisomerase I inhibitor (brengitecan) that causes DNA damage and kills the cell.
Izalontamab brengitecan (BMS-986507), a bispecific EGFR/HER3-targeted antibody–drug conjugate that is internalized upon binding and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific EGFR/HER3-targeted antibody–drug conjugate that binds EGFR- and HER3-expressing tumor cells, is internalized, and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
YES
DIRECT
The EGFR/HER3-targeted ADC binds HER3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor (brengitecan) that causes DNA damage leading to cell death.
Izalontamab brengitecan (BMS-986507), a bispecific EGFR/HER3-targeted antibody–drug conjugate that is internalized upon binding and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific EGFR/HER3-targeted antibody–drug conjugate that binds EGFR- and HER3-expressing tumor cells, is internalized, and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
NO
INDIRECT
BL-B01D1 binds EGFR/HER3 on tumor cells, is internalized, and releases a topoisomerase I–inhibiting payload that causes DNA damage. DNA topoisomerase I is the intracellular enzymatic target of the payload, not the ADC’s binding antigen.